Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on September 7, 2022. The filing addresses a corporate event regarding the company's capital raising activities under its existing Equity Distribution Agreement (EDA) with Piper Sandler & Co.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the authorization of a new equity offering.
Material Changes
- Equity Offering Authorization: The Company filed a prospectus supplement to offer up to an additional $35.0 million of shares of common stock.
- Agreement Update: This offering is pursuant to the EDA dated September 11, 2019, as amended on March 26, 2021.
- Registration Statement Transition: The previous 2019 Registration Statement (No. 333-233716) is set to expire on September 17, 2022. The Company will cease using the 2021 Prospectus upon the filing of this new Prospectus Supplement under the 2021 shelf registration statement on Form S-3 (333-254775).
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the standard disclosure of the equity offering mechanics. The primary contingency noted is the expiration of the prior registration statement on September 17, 2022, necessitating this update to continue the at-the-market offering program.
Investor Verification Checklist
- Verify the final number of shares issued and the actual proceeds raised from the $35.0 million offering authorization.
- Confirm the effective date of the new Prospectus Supplement and the cessation of the 2021 Prospectus.
- Review the legal opinion of Dechert LLP (Exhibit 5.1) regarding the validity of the shares to be issued.
- Monitor subsequent filings for the actual execution of sales under the updated EDA.